

PE/Cyanine7 anti-mouse CD3 ϵ Antibody

Catalog# / Size	100319 / 25 μ g 100320 / 100 μ g
Clone	145-2C11
Regulatory Status	RUO
Other Names	CD3 ϵ , T3, CD3
Isotype	Armenian Hamster IgG
Description	CD3 ϵ is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3 ϵ forms a TCR complex by associating with the CD3 δ , γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	H-2K ^b -specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 μ g per million cells in 100 μ l volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes	Clone 145-2C11 is useful for <i>in vitro</i> blocking of target-specific CTL-mediated cell lysis ¹ , as well as T cell activation assays, inducing proliferation and cytokine production ^{1,2,7,12,16} . It also induces apoptosis in immature thymocytes ³² , and <i>in vivo</i> T cell depletion ⁸⁻¹⁰ . Additional reported applications (for relevant formats of this clone) include: immunoprecipitation ¹ , immunohistochemical staining ^{14,15} of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting ⁴ , complement-mediated cytotoxicity ⁶ , <i>in vitro</i> and <i>in vivo</i> stimulation of T cells ^{1,2,7,12,16} , immunofluorescent staining ⁵ , and <i>in vivo</i> T cell depletion ⁸⁻¹⁰ . The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells ¹¹ . Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/ μ g, Azide-Free, 0.2 μ m filtered) is recommended for functional assays (Cat. No. 100314). For <i>in vivo</i> studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/ μ g).
Additional Product Notes	BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates
BioLegend citation)

1. Leo O, *et al.* 1987. *P. Natl. Acad. Sci. USA* 84:1374. (IP, Activ, Block)
2. Kruisbeek AM, *et al.* 1991. *In Current Protocols in Immunology*. 3.12.1. (Activ)
3. Duke RC, *et al.* 1995. *Current Protocols in Immunology*. 3.17.1.
4. Salvadori S, *et al.* 1994. *J. Immunol.* 153:5176. (WB)
5. Payer E, *et al.* 1991. *J. Immunol.* 146:2536. (IF)
6. Jacobs H, *et al.* 1994. *Eur. J. Immunol.* 24:934. (CMCD)
7. Vossen ACTM, *et al.* 1995. *Eur. J. Immunol.* 25:1492. (Activ)
8. Henrickson M, *et al.* 1995. *Transplantation* 60:828. (Deplete)
9. Kinnaert P, *et al.* 1996. *Transpl. Int.* 9:386. (Deplete)
10. Han WR, *et al.* 1999. *Transpl. Immunol.* 7:207. (Deplete)
11. Miescher GC, *et al.* 1989. *Immunol. Lett.* 23:113. (Block)
12. Terrazas LI, *et al.* 2005. *Intl. J. Parasitology*. 35:1349. (Activ)
13. Ko SY, *et al.* 2005. *J. Immunol.* 175:3309.
14. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC-F)
15. Tilley SL, *et al.* 2007. *J. Immunol.* 178:3208. (IHC-F)
16. Wang W, *et al.* 2007. *J. Immunol.* 178:4885. (Activ)
17. Xiao S, *et al.* 2007. *J. Exp. Med.* 204:1691.
18. Chappaz S, *et al.* 2007. *Blood* doi:10.1182/blood-2007-02-074245. (FC) [PubMed](#).
19. Curtsinger JM, *et al.* 2005. *J. Immunol.* 175:4392. [PubMed](#)
20. Guo Y, *et al.* 2008. *Blood* 112:480. [PubMed](#)
21. Kenna TJ, *et al.* 2008. *Blood* 111:2091.
22. Perchonock CE, *et al.* 2007. *J. Immunol.* 179:1768. [PubMed](#)
23. Perchonock GE, *et al.* 2006. *Mol. Cell. Biol.* 26:6005. [PubMed](#)
24. Kanaya T, *et al.* 2008. *Am. J. Physiol. Gastrointest. Liver Physiol.* 295:G273. [PubMed](#)
25. de Koning BA, *et al.* 2006. *Int. Immunol.* 18:941. [PubMed](#)
26. Schulteis RD, *et al.* 2008. *Blood* 295:G273. [PubMed](#)
27. Qi Q, *et al.* 2009. *Blood* 114:564. [PubMed](#)
28. Helmersson S, *et al.* 2013. *Am J Pathol.* 9440:123. [PubMed](#)
29. Wu S, *et al.* 2014. *Clin Vaccine Immunol.* 21:156. [PubMed](#)
30. Yan J, *et al.* 2014. *Vaccine.* 32:2833. [PubMed](#)
31. Guitierrez DA, *et al.* 2014. *Diabetes.* 63:3827. [PubMed](#)
32. Shi YF, *et al.* 1991. *J Immunol.* 146:3340. (Apop)

Product Citations

1. Huang Y, *et al.* 2015. *Proc Natl Acad Sci U S A.* 112:39. [PubMed](#)
2. Cabañero D, *et al.* 2020. *Elife.* 9:00. [PubMed](#)
3. Tran NT, *et al.* 2019. *Cell Rep.* 28:3510. [PubMed](#)
4. Strickley JD, *et al.* 2019. *Nature.* 575:519. [PubMed](#)
5. Dong MB, *et al.* 2020. *Cell.* 178(5):1189-1204.e23. [PubMed](#)
6. Aguilar EG, *et al.* 2021. *Blood Adv.* 5:4219. [PubMed](#)
7. Oetjen LK *et al.* 2017. *Cell.* 171(1):217-228. [PubMed](#)
8. Zhou J, *et al.* 2019. *Immunity.* 50:403. [PubMed](#)
9. Tatsuguchi T, *et al.* 2022. *Int Immunol.* 34:277. [PubMed](#)
10. Zhu H, *et al.* 2018. *Elife.* 7. [PubMed](#)
11. Buxadé M, *et al.* 2018. *J Exp Med.* 215:2901. [PubMed](#)
12. Yang C, *et al.* 2021. *J Immunother Cancer.* 9. [PubMed](#)
13. Chen L, *et al.* 2022. *Mol Ther Oncolytics.* 24:522. [PubMed](#)
14. Li ZX, *et al.* 2022. *Arch Virol.* [PubMed](#)
15. Huai W, *et al.* 2019. *J Exp Med.* 216:772. [PubMed](#)
16. Tan L, *et al.* 2019. *Cell Rep.* 27:3657. [PubMed](#)
17. Schulthess J *et al.* 2019. *Immunity.* 50(2):432-445. [PubMed](#)
18. Gopinathan G, *et al.* 2022. *Mol Cancer Ther.* 21:1030. [PubMed](#)
19. Ma C, *et al.* 2022. *Proc Natl Acad Sci U S A.* 119. [PubMed](#)
20. Zhao B, *et al.* 2021. *Cell Reports.* 36(3):109401. [PubMed](#)
21. Bartleson JM, *et al.* 2020. *Nat Immunol.* 1384:21. [PubMed](#)
22. Demircioglu F, *et al.* 2020. *Nat Commun.* 11:1290. [PubMed](#)
23. Yang W, *et al.* 2020. *Mucosal Immunol.* 13:788. [PubMed](#)
24. Li Z, *et al.* 2022. *Elife.* 11. [PubMed](#)
25. Cousin N, *et al.* 2021. *Cancer Res.* 81:4133. [PubMed](#)
26. Tuttle KD, *et al.* 2020. *Cell Rep.* 33:108407. [PubMed](#)
27. Xiao Y, *et al.* 2021. *Cancer Cell.* 39(3):423-437.e7. [PubMed](#)
28. Emgård J, *et al.* 2018. *Immunity.* 143:419. [PubMed](#)
29. Alexander RK, *et al.* 2020. *eLife.* 9:e54090. [PubMed](#)
30. Chun E, *et al.* 2020. *Immunity.* 51(5):871-884.e6. [PubMed](#)
31. Deng Z, *et al.* 2017. *Oncogene.* 36:639. [PubMed](#)
32. Westfall S, *et al.* 2020. *Brain Behav Immun.* [PubMed](#)
33. He Y, *et al.* 2021. *Cell Metabolism.* 33(5):988-1000.e7. [PubMed](#)
34. Schadt L, *et al.* 2020. *Cell Reports.* 29(5):1236-1248.e7. [PubMed](#)
35. Wu Y, *et al.* 2021. *Nat Commun.* 12:2346. [PubMed](#)
36. Alikhanyan K, *et al.* 2021. *Cancers (Basel).* 13. [PubMed](#)
37. Synn CB, *et al.* 2022. *Clin Transl Immunology.* 11:e1364. [PubMed](#)
38. Tacconi C, *et al.* 2021. *Cell Reports.* 35(2):108993. [PubMed](#)
39. Lu M, *et al.* 2021. *J Virol.* 95:e0059221. [PubMed](#)
40. Alikhanyan K, *et al.* 2020. *Immun Inflamm Dis.* 8:181. [PubMed](#)
41. Tran NT, *et al.* 2020. *STAR Protocols.* 1(1):100028. [PubMed](#)
42. Murakami R, *et al.* 2013. *PLoS One.* 8:73270. [PubMed](#)
43. Williams JW, *et al.* 2017. *Circ Res.* 121:662. [PubMed](#)
44. Kubota S, *et al.* 2019. *Nat Commun.* 10:1653. [PubMed](#)
45. Wu S, *et al.* 2022. *BMC Immunol.* 23:17. [PubMed](#)

46. Wang R, *et al.* 2022. *Front Immunol.* 13:947756. [PubMed](#)
47. De Ponte Conti B, *et al.* 2021. *Elife.* 10:. [PubMed](#)
48. Peng L, *et al.* 2022. *Cell Rep Med.* 3:100634. [PubMed](#)
49. Li J, *et al.* 2013. *Arch Immunol Ther Exp (Warsz).* 61:237. [PubMed](#)
50. Huang Y, *et al.* 2016. *J Immunol.* 196: 217 - 231. [PubMed](#)
51. Uematsu T, *et al.* 2016. *Sci Rep.* 6:37815. [PubMed](#)
52. Wang H, *et al.* 2020. *Nat Mater.* 1.655555556. [PubMed](#)
53. Shiozawa S, *et al.* 2022. *iScience.* 25:103537. [PubMed](#)
54. Chen C, *et al.* 2021. *J Virol.* 95:e0082921. [PubMed](#)
55. Riva A, *et al.* 2017. *PLoS One.* 10.1371/journal.pone.0181964. [PubMed](#)
56. Yasuma K, *et al.* 2016. *PLoS Pathog.* 12: 1005372. [PubMed](#)
57. Maniati E, *et al.* 2020. *Cell Rep.* 30:525. [PubMed](#)
58. Damgaard RB *et al.* 2016. *Cell.* 166(5):1215-1230 . [PubMed](#)
59. Zhao N, *et al.* 2018. *J Clin Invest.* 26:84. [PubMed](#)
60. Leary N, *et al.* 2022. *J Extracell Vesicles.* 11:e12197. [PubMed](#)
61. Takahashi T, *et al.* 2017. *J Exp Med.* 10.1084/jem.20160247. [PubMed](#)
62. Halim TYF *et al.* 2018. *Immunity.* 48(6):1195-1207 . [PubMed](#)
63. Yoshida H, *et al.* 2019. *Cell.* 176:897. [PubMed](#)
64. Ireland L, *et al.* 2020. *Front Immunol.* 11:297. [PubMed](#)
65. Hong JP, *et al.* 2020. *Cell Reports Medicine.* 1(3):100035. [PubMed](#)
66. Qi Q, *et al.* 2009. *Blood.* 114:564. [PubMed](#)
67. Tzeng TT, *et al.* 2022. *NPJ Vaccines.* 7:60. [PubMed](#)
68. Fitzpatrick Z, *et al.* 2020. *Nature.* 587:472. [PubMed](#)
69. Chen J, *et al.* 2014. *Cell Res.* 24:1050. [PubMed](#)
70. Walker JA, *et al.* 2020. *Immunity.* 51(1):104-118. [PubMed](#)
71. White JP *et al.* 2018. *Cell.* 175(5):1198-1212 . [PubMed](#)
72. Tippimanchai DD, *et al.* 2018. *Oncoimmunology.* 7:e1438105. [PubMed](#)
73. Celorrio M, *et al.* 2022. *Acta Neuropathol Commun.* 10:10. [PubMed](#)
74. Fite BZ, *et al.* 2021. *Sci Rep.* 11:927. [PubMed](#)
75. Wang Y, *et al.* 2020. *Immunity.* 53(6):1168-1181.e7. [PubMed](#)
76. Goc J, *et al.* 2021. *Cell.* .: [PubMed](#)
77. Li Z *et al.* 2018. *Immunity.* 49(4):640-653 . [PubMed](#)
78. Ioanna E Galani *et al.* 2017. *Immunity.* 46(5):875-890 . [PubMed](#)
79. Nabekura T, *et al.* 2020. *Immunity.* 96:52. [PubMed](#)
80. Uematsu T, *et al.* 2015. *Sci Rep.* 5: 17577. [PubMed](#)

RRID AB_312684 (BioLegend Cat. No. 100319)
 AB_312685 (BioLegend Cat. No. 100320)

Antigen Details

Structure	lg superfamily, forms CD3/TCR complex with CD3 δ , γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution	Thymocytes (differentiation dependent), mature T cells, NK-T cells
Function	TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor	Peptide antigen/MHC-complex
Cell Type	NKT cells, T cells, Thymocytes, Tregs
Biology Area	Immunology
Molecular Family	CD Molecules, TCRs
Antigen References	<ol style="list-style-type: none"> 1. Barclay A, <i>et al.</i> 1997. <i>The Leukocyte Antigen FactsBook</i> Academic Press. 2. Davis MM. 1990. <i>Annu. Rev. Biochem.</i> 59:475. 3. Weiss A, <i>et al.</i> 1994. <i>Cell</i> 76:263.
Gene ID	12501


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

APC anti-mouse CD3 ϵ , Biotin anti-mouse CD3 ϵ , FITC anti-mouse CD3 ϵ , PE anti-mouse CD3 ϵ , PE/Cyanine5 anti-mouse CD3 ϵ , Purified anti-mouse CD3 ϵ , PE/Cyanine7 anti-mouse CD3 ϵ , Alexa Fluor® 488 anti-mouse CD3 ϵ , Alexa Fluor® 647 anti-mouse CD3 ϵ , PerCP anti-mouse CD3 ϵ , PerCP/Cyanine5.5 anti-mouse CD3 ϵ , Purified anti-mouse CD3 ϵ (Maxpar® Ready), APC/Cyanine7 anti-mouse CD3 ϵ , Pacific Blue™ anti-mouse CD3 ϵ , Brilliant Violet 421™ anti-mouse CD3 ϵ , Ultra-LEAF™ Purified anti-mouse CD3 ϵ , PE/Dazzle™ 594 anti-mouse CD3 ϵ , Brilliant Violet 510™ anti-mouse CD3 ϵ , Brilliant Violet 605™ anti-mouse CD3 ϵ , Brilliant Violet 711™ anti-mouse CD3 ϵ , Brilliant Violet 785™ anti-mouse CD3 ϵ , APC/Fire™ 750 anti-mouse CD3 ϵ , GolnVivo™ Purified anti-mouse CD3 ϵ , Spark YG™ 593 anti-mouse CD3

Product Data



C57BL/6 mouse splenocytes were stained with CD3 ϵ (clone 145-2C11) PE/Cyanine7 (filled histogram) or Armenian hamster IgG PE/Cyanine7 isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587